צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים: krystalbio.com (KRYS)

Krystal Biotech, Inc. (KRYS) is a leading pioneer in skin gene therapy with colossal investments in unique drug delivery methods. The GURU.Markets system generates this chart, where the amplitude of quarterly EPS fluctuations demonstrates that the -23.20 level is the current value. The company's flawless image relies on the trust of patients with rare pathologies, yet its financial stability is based primarily on sales of the drug Vyjuvek.
פילוחים אנליטיים של חברת Krystal Biotech, Inc.

Quarterly EPS growth reflects the dynamics of net income per share relative to the same period last year. This metric allows a value investor to identify undervalued assets with a high margin of safety. For Krystal Biotech, Inc. (KRYS), this indicator confirms the effectiveness of commercializing its gene delivery platform for treating dermatological pathologies. By analyzing the quarterly EPS increase, one can assess the scalability of the business model, which serves as a safeguard against purchasing overvalued securities at the peak of the cycle.